

Substitute for form 1449A/PTO					
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					
<i>(Use as many sheets as necessary)</i>					
Sheet	1	of	1		
				Attorney Docket Number	13566.105020

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
/J.L./		Chabner et al., Cancer Chemotherapy and Biotherapy: Principles and Practice, Third Edition, pages 1-16, 2001			
/J.L./		Forouzesh et al., Internet Archive, Internet Archive Entry for Proc. Am. Soc. Clin. Oncol. ASCO meeting, Abstract 373, June 3, 2001, 32 pages			
/J.L./		Perotti et al., "Cardiotoxic effects of anthracycline-taxane combinations," Expert Opin Drug Saf, 2(1), 59-71, January 2003			
/J.L./		PR Newswire, PR Newswire, October 14, 2001, 4 pages			
/J.L./		Rote Liste 2002 "Doxorubicin," entries 86-056 through 86-062, 2002			
/J.L./		Slamon et al., "Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2", New England Journal of Medicine, 2001, 344(11):783-92			

Examiner Signature	/Jonathan Lau/	Date Considered	03/27/2009
--------------------	----------------	-----------------	------------